Cross-protocol comparison of iPSC-microglia reveals hypofunction contributes to neuronal vulnerability and synaptic alterations in the MAPT-S305N model of frontotemporal dementia.

Abstract

Progressive and chronic neuroinflammation is associated with numerous neurodegenerative diseases, including primary tauopathies such as frontotemporal dementia and progressive supranuclear palsy. Unlike Alzheimers disease, there is no clear genetic association implicating microglial dysfunction as a primary driver of tauopathy. As such, the contributions of microglia to tauopathy pathogenesis have been less well defined. Here, we explore the cell autonomous effects of the pathogenic MAPT-S305N variant on microglial function, across two distinct iPSC-microglia protocols, followed by examination of the non-cell autonomous effects of microglial MAPT genotype on neuronal health and function. We find that different protocols produce cells of equivalent microglial identity, but result in microglia in different functional states, thereby influencing reactivity and detectable phenotypes. Regardless, across both protocols we find that MAPT-S305N induces microglial hypoactivity, evidenced by impaired phagocytosis, reduced cytokine release and diminished regulation of synaptic function. We conclude that microglial hypoactivity may be an early event in disease pathogenesis, where MAPT mutation microglia fail to adequately respond to pathogenic stimuli, thereby contributing to subsequent neuronal vulnerability and susceptibility. Further studies are required to understand how and when this initial hypoactive state may switch to a toxic pro-inflammatory state, and whether early detection and correction may be of therapeutic value.